Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Repare Therapeutics (RPTX) announced the acceptance of six abstracts for presentation at the AACR Annual Meeting 2025 in Chicago.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Mini-Oral Presentation Details:
Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)
Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center
Session: Innovative Approaches to Key Molecular Targets
Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT
Location: Room S406 (Vista Ballroom)
Abstract Number: CT262
Title: The PLK4 inhibitor
Presenter: John M. Maris, MD, Children’s Hospital of
Session: Advancing the Science of Childhood Cancers: From Bench to Bedside
Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT
Location: Room E353 C
Abstract Number: 1201
Poster Presentation Details:
Title: A dual mechanism of sensitivity to PLK4 inhibition by
Presenter: Michal Zimmermann, PhD, Repare Therapeutics
Session: Cell Cycle Effects of Anticancer Drugs
Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT
Location: Poster Section 17
Poster Number: 9
Abstract Number: 365
Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors
Presenter: Anne Roulston, PhD, Repare Therapeutics
Session: Kinase and Phosphatase Inhibitors 1
Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT
Location: Poster Section 21
Poster Number: 9
Abstract Number: 1734
Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools
Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics
Session: Diagnostic Biomarkers 2
Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT
Location: Poster Section 31
Poster Number: 2
Abstract Number: 717
Title: Targeting CCNE1 amplification in gastric cancer
Presenter: Sung Joo Jang, Columbia University Irving Medical Center
Session: Protein Kinases and Phosphatases as Targets for Therapy
Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT
Location: Poster Section 24
Poster Number: 4
Abstract Number: 6942
A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session.
About Repare Therapeutics Inc.
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s clinical-stage pipeline includes
View source version on businesswire.com: https://www.businesswire.com/news/home/20250425074570/en/
Investor Relations & Media Contact:
Matthew DeYoung
Investor Relations and Media
Argot Partners
investors@reparerx.com
Source: Repare Therapeutics Inc.